Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Patient Care
Patient Monitoring
Return to: MDBR Home | Patient Care | Patient Monitoring

Novartis’ Alcon to introduce new Clareon intraocular lens

MDBR Staff Writer Published 04 October 2017

Novartis subsidiary Alcon is set to introduce new Clareon intraocular lens (IOL) at this year’s European Society of Cataract and Refractive Surgeons (ECRS) congress in Portugal.

The XXXV ESCRS congress will take place between 7 and 11 October in Lisbon.

Clareon IOL, which is developed by using an advanced optic material, is delivered through an automated, disposable and pre-loaded delivery system.

In July this year, Alcon secured CE mark approval for Clareon monofocal IOL, which is Alcon’s next-generation polymer material.

At the event, the company will also exhibit AcrySof family of IOLs, which are used in the treatment of concomitant visual conditions such as astigmatism, presbyopia and glaucoma along with cataracts.

Alcon will also present CyPass micro-stent, which is a minimally invasive glaucoma surgical (MIGS) device to treat patients with mild-to-moderate primary open-angle glaucoma in conjunction with cataract surgery.

It can also be used in a standalone procedure in patients with primary open-angle glaucoma who have failed previous medical treatments.

CyPass is claimed to be the first MIGS device designed to be implanted in the supraciliary space.

Alcon CEO Mike Ball said: “We are proud to deliver on our commitment to bring innovations to the surgical community, and Clareon is one of the biggest breakthroughs in the IOL space.

“This is a great year for Alcon as we celebrate many important milestones – from fulfilling our mission to help people see better by enhancing and transforming the way surgeons treat cataracts through innovations like Clareon, to marking the 100 millionth implant of our flagship AcrySof lenses.”


Image: Novartis headquarters in Basel, Switzerland. Photo: courtesy of Novartis AG